Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2010

Study Completion Date

April 30, 2011

Conditions
B-Cell Lymphoma
Interventions
DRUG

Clofarabine

The starting dose of clofarabine will be 10 mg/m2 once a week for 3 weeks repeated every 4 weeks with dose escalations to 15, 20 , 30 and 40 mg/m2/week.

Trial Locations (1)

06520

Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Yale University

OTHER

NCT00338494 - Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma | Biotech Hunter | Biotech Hunter